{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-134749","form_type":"8-K","ticker":"CRDF","cik":"0001213037","company_name":"Cardiff Oncology, Inc.","filed_at":"2024-12-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:07.882720+00:00","generated_at":"2026-05-29T05:02:56.126761+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Cardiff Oncology announces Phase 2 CRDF-004 data: 64% ORR in 30mg onvansertib arm vs 33% control","bullets":["30mg onvansertib+SoC 64% ORR (7/11) vs 33% (3/9) control; 20mg arm 50% ORR (5/10).","Onvansertib well-tolerated; no major or unexpected toxicities at either dose.","Additional CRDF-004 clinical data expected in 1H 2025.","Conference call held Dec 10, 2024 at 8:00 AM ET."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-134749","json":"https://secwatch.observer/filing/0000950170-24-134749.json","markdown":"https://secwatch.observer/filing/0000950170-24-134749.md","text":"https://secwatch.observer/filing/0000950170-24-134749.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1213037/000095017024134749/0000950170-24-134749-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1213037/000095017024134749/crdf-20241210.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T05:02:56.126761+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}